Instrument Inactif

Communiqués Charming Shoppes, Inc.

Actions

US1611331034

Détaillant habillement et accessoires

Cours en clôture Nasdaq
- ^USD	-

Communiqués

01/06/17	Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program	GL
17/05/17	Coherus BioSciences Prevails in ‘135 IPR Decision	GL
08/05/17	Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results	GL
01/05/17	Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May	GL
25/04/17	Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar	GL
24/04/17	Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th	GL
27/03/17	Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development	GL
13/03/17	Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results	GL
06/03/17	Coherus Addresses Trade Secret Action Filed by Amgen	GL
02/03/17	Statement by Coherus CEO Regarding Biosimilars User Fees	GL
02/03/17	Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint	GL
01/03/17	Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March	GL
21/02/17	Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th	GL
17/02/17	Coherus BioSciences Announces New Employment Inducement Grants	GL
08/02/17	Coherus Prices Public Offering of Common Stock	GL
07/02/17	Coherus Announces Proposed Public Offering of Common Stock	GL
31/01/17	Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619	GL
10/01/17	Charming Shoppes : Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis	PU
10/01/17	Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis	GL
04/01/17	Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference	GL
29/11/16	Coherus’ Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted	GL
18/11/16	Coherus BioSciences Announces New Employment Inducement Grants	GL
09/11/16	Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results	GL
07/11/16	Coherus BioSciences Receives Decision Denying Institution of the ‘166 IPR Related to AbbVie’s HUMIRA® Formulation	GL
04/11/16	Coherus BioSciences Announces New Employment Inducement Grants	GL